Ahmed Al Jebawi, MD
Endocrinology, Diabetes & Metabolism · Anderson, INNPI 1306839030
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $723 and has fallen 95.4% since, to $33 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in IN, where the typical reported total is $1,569.
Across 48 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$110
- Novo Nordisk$95
- Mannkind Corporation$80
- Shire North American Group Inc$65
- Sanofi-aventis U.S. LLC$57
- Bayer$53
- plus $347 from 15 others
Across 27 payments — averaging $2156.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$58K
What the payments were for
- Food & beverage$78097%
- Education$263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $110 |
| Novo Nordisk | 6 | $95 |
| Mannkind Corporation | 4 | $80 |
| Shire North American Group Inc | 4 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Bayer | 3 | $53 |
| Amgen | 3 | $49 |
| Insulet Corporation | 2 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Valeritas, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Medtronic | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$806 in reported general payments places this provider in the 40th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,152 | $1,775,266 |
| MounjaroTirzepatide | 491 | $682,510 |
| JardianceEmpagliflozin | 472 | $547,171 |
| TrulicityDulaglutide | 259 | $369,909 |
| Humalog Kwikpen U-200Insulin Lispro | 114 | $302,745 |
| Humalog Kwikpen U-100Insulin Lispro | 430 | $204,485 |
| GenotropinSomatropin | 37 | $197,975 |
| Tresiba Flextouch U-100Insulin Degludec | 238 | $197,855 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $170,006 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 166 | $166,854 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 151 | $165,012 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 872 | $151,646 |
| Tresiba Flextouch U-200Insulin Degludec | 80 | $142,133 |
| FarxigaDapagliflozin Propanediol | 135 | $137,954 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 103 | $120,439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $95 | $1,858,2761,261 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $32 | $1,084,042860 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $12 | $712,183623 claims |
| MerckJanuvia, Janumet Xr | $15 | $204,275191 claims |
| AstraZenecaFarxiga | $110 | $137,954135 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $57 | $66,90051 claims |
| BayerKerendia | $53 | $17,34813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Anderson
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.